# Glucocorticoid Treatment in Transaortic Valve Replacement to Reduce the Incidence of Conduction Disturbances (GLUCO-TAVR).

Study · id `cardio:ct-nct06076824` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06076824](<https://clinicaltrials.gov/study/NCT06076824>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06076824

Browse, organ or system: Heart  
Browse, condition area: Heart rhythm problems; Valve and congenital heart disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

## Technical summary

Registry record NCT06076824. Randomized; single masking; primary purpose prevention. Start 2023-08-12 (actual); primary completion 2024-09-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT06076824, source copy `cardio:ctgov-nct06076824-2023-10-11`, retrieved 2026-10-26)
- Started: 2023-08-12 (actual) (ClinicalTrials.gov record NCT06076824, source copy `cardio:ctgov-nct06076824-2023-10-11`, retrieved 2026-10-26)
- Primary completion: 2024-09-01 (anticipated) (ClinicalTrials.gov record NCT06076824, source copy `cardio:ctgov-nct06076824-2023-10-11`, retrieved 2026-10-26)
- Completion: 2024-09-01 (anticipated) (ClinicalTrials.gov record NCT06076824, source copy `cardio:ctgov-nct06076824-2023-10-11`, retrieved 2026-10-26)
- Countries: Spain (ClinicalTrials.gov record NCT06076824, source copy `cardio:ctgov-nct06076824-2023-10-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06076824-2023-10-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: Glucocorticoid Treatment in Transaortic Valve Replacement to Reduce the Incidence of Conduction Disturbances (GLUCO-TAVR).
- Acronym: GLUCO-TAVR
- Condition: Heart Block
- Condition: Aortic Stenosis
- Condition: Bundle-Branch Block
- Intervention (Drug): Methylprednisolone
- Intervention (Other): Placebo
- Lead sponsor: Hospital General Universitario de Alicante
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Heart block (`cardio:heart-block`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)

## Provenance

Content hash: c0505de731589130409b65445d829bc73b4fe354bf2179cd35302d09f23ac817
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
